Stay updated with breaking news from Tom Riga. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good day and thank you for standing by. Welcome to the Spectrum Pharmaceuticals 4Q 2022 Earnings Call. At this time, all participants are in a listen-only mode.
31.01.2023 - Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology, today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022. Business ... Seite 1
The FDA has issued a complete response letter to Spectrum Pharmaceuticals regarding the new drug application for poziotinib.
The FDA has issued a Complete Response Letter to Spectrum Pharmaceuticals regarding the New Drug Application for poziotinib.
The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations.